IP Library Granted Patent US 10,307,385
Granted Patent B2
US 10,307,385 · App. 14/423,882 · Granted Jun 4, 2019

Gelling formulation containing ketamine

Inventors: Vincent Boudy (Paris, FR); Annick Tibi (Charenton, FR); Benoît D'Hayer (Paris, FR); Marie-Caroline Husson (Paris, FR); Sandrine Graff De Faget (La Celle Saint Cloud, FR)
Assignee: Assistance Publique-Hopitaux de Paris
A61K31/135A61K9/006A61K9/06A61K47/34A61P23/00A61P23/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,307,385
App. No.
14/423,882
Granted
Jun 4, 2019
Kind
B2
Abstract

A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.

Claims (26)

1. A liquid gelling formulation comprising ketamine or a pharmaceutically acceptable salt thereof, 15 to 20 g/100 ml of a poloxamer, from 1 to 2 g/100 ml of at least one pharmaceutically acceptable mucoadhesive agents, and water.

2. The liquid gelling formulation as claimed in claim 1 , wherein the ketamine is the S-(+) enantiomer of ketamine or a pharmaceutically acceptable salt thereof.

3. The liquid gelling formulation as claimed in claim 1 , comprising from 2 to 20 g/100 ml of ketamine or of a pharmaceutically acceptable salt thereof.

4. The liquid gelling formulation as claimed in claim 1 , comprising from 16 to 19 g/100 ml of poloxamer.

5. The liquid gelling formulation as claimed in claim 1 , wherein the poloxamer is chosen from poloxamer 407, poloxamer 188, or a mixture thereof.

6. The liquid gelling formulation as claimed in claim 1 , also comprising one or more pharmaceutically acceptable excipients chosen from taste-masking agents, acidic agents, basic agents, preservatives, sodium chloride and potassium chloride.

7. The liquid gelling formulation as claimed in claim 1 , characterized in that the gelling formulation as a whole is sterile.

8. The liquid gelling formulation as claimed in claim 1 , characterized in that it is intended for sublingual administration.

9. The liquid gelling formulation as claimed in claim 1 , characterized in that it is intended to be sprayed in the form of a liquid spray into the buccal cavity.

10. A pharmaceutical composition comprising formulation as claimed in claim 1 .

11. A method of treating an individual suffering from pain comprising the step of administering the liquid gelling formulation of claim 1 .

12. The method as claimed in claim 11 , wherein the formulation is sprayed in the form of a liquid spray into the buccal cavity.

13. A method for preparing a liquid gelling formulation as claimed in claim 1 , said method comprising the steps of:

i) dissolving, under cold conditions, the poloxamer in water;

ii) adding and dissolving one or more mucoadhesive agents;

iii) adding and dissolving ketamine or a salt thereof to and in the solution obtained in step i), at ambient temperature; and

iv) recovering the formulation obtained.

14. A method for preparing a liquid gelling formulation as claimed in claim 1 , said method comprising the steps of:

i) dissolving ketamine or a salt thereof in water, at ambient temperature;

ii) adding and dissolving one or more mucoadhesive agents at a temperature between +40° C. and +70° C.;

iii) adding and dissolving the poloxamer to and in the solution obtained in step i) cooled beforehand, at a temperature between +8° C. and +16° C.; and

iv) recovering the formulation obtained.

15. The method of claim 14 , wherein the step of dissolving ketamine or a salt thereof in water is at a temperature between +15° C. and +25° C.

16. The method of claim 13 , wherein the step of

dissolving the poloxamer in water is at a temperature between +8° C. and +16° C., the step of adding and dissolving one or more mucoadhesive agents is at a temperature between +40° C. and +70° C., and the step of adding and dissolving ketamine or a salt thereof to and in the solution obtained in step i), is at a temperature between +15° C. and +25° C.

17. A pharmaceutical composition consisting of the formulation as claimed in claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2015
From: BOUDY, VINCENT; TIBI, ANNICK; D'HAYER, BENOIT; HUSSON, MARIE-CAROLINE; GRAFF DE FAGET, SANDRINE
To: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
Reel/Frame 035525/0240 →
Priority Claims (1)
FR 12 58146 · Aug 31, 2012 · national
Continuity (1)
Related Publication 20150224070A1 · Aug 13, 2015